BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lopes-Pacheco M. CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine. Front Pharmacol 2019;10:1662. [PMID: 32153386 DOI: 10.3389/fphar.2019.01662] [Cited by in Crossref: 63] [Cited by in F6Publishing: 56] [Article Influence: 31.5] [Reference Citation Analysis]
Number Citing Articles
1 Fukuda R, Okiyoneda T. Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Ubiquitylation as a Novel Pharmaceutical Target for Cystic Fibrosis. Pharmaceuticals (Basel) 2020;13:E75. [PMID: 32331485 DOI: 10.3390/ph13040075] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Guichard M, Wilms T, Mahri S, Patil HP, Hoton D, Ucakar B, Vanvarenberg K, Cheou P, Beka M, Marbaix E, Leal T, Vanbever R. PEGylation of Recombinant Human Deoxyribonuclease I Provides a Long‐Acting Version of the Mucolytic for Patients with Cystic Fibrosis. Adv Therap 2021;4:2000146. [DOI: 10.1002/adtp.202000146] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
3 O'shea KM, O'carroll OM, Carroll C, Grogan B, Connolly A, O'shaughnessy L, Nicholson TT, Gallagher CG, Mckone EF. Efficacy of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease. Eur Respir J 2021;57:2003079. [DOI: 10.1183/13993003.03079-2020] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
4 Capurro V, Tomati V, Sondo E, Renda M, Borrelli A, Pastorino C, Guidone D, Venturini A, Giraudo A, Mandrup Bertozzi S, Musante I, Bertozzi F, Bandiera T, Zara F, Galietta LJV, Pedemonte N. Partial Rescue of F508del-CFTR Stability and Trafficking Defects by Double Corrector Treatment. Int J Mol Sci 2021;22:5262. [PMID: 34067708 DOI: 10.3390/ijms22105262] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
5 Gavioli EM, Guardado N, Haniff F, Deiab N, Vider E. A current review of the safety of cystic fibrosis transmembrane conductance regulator modulators. J Clin Pharm Ther 2021;46:286-94. [PMID: 33285018 DOI: 10.1111/jcpt.13329] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Abdallah K, De Boeck K, Dooms M, Simoens S. A Comparative Analysis of Pricing and Reimbursement of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Europe. Front Pharmacol 2021;12:746710. [PMID: 34858177 DOI: 10.3389/fphar.2021.746710] [Reference Citation Analysis]
7 Lee AJ, Huffmyer JL, Thiele EL, Zeitlin PL, Chatterjee D. The Changing Face of Cystic Fibrosis: An Update for Anesthesiologists. Anesth Analg 2022. [PMID: 35020677 DOI: 10.1213/ANE.0000000000005856] [Reference Citation Analysis]
8 Lukasiak A, Zajac M. The Distribution and Role of the CFTR Protein in the Intracellular Compartments. Membranes (Basel) 2021;11:804. [PMID: 34832033 DOI: 10.3390/membranes11110804] [Reference Citation Analysis]
9 Pereira C, Mazein A, Farinha CM, Gray MA, Kunzelmann K, Ostaszewski M, Balaur I, Amaral MD, Falcao AO. CyFi-MAP: an interactive pathway-based resource for cystic fibrosis. Sci Rep 2021;11:22223. [PMID: 34782688 DOI: 10.1038/s41598-021-01618-3] [Reference Citation Analysis]
10 Scano M, Benetollo A, Nogara L, Bondì M, Barba FD, Soardi M, Furlan S, Akyurek EE, Caccin P, Carotti M, Sacchetto R, Blaauw B, Sandonà D. CFTR corrector C17 is effective in muscular dystrophy, in vivo proof of concept in LGMDR3. Hum Mol Genet 2021:ddab260. [PMID: 34505136 DOI: 10.1093/hmg/ddab260] [Reference Citation Analysis]
11 Kotsimbos T, Kaye D, Keating D. Pulmonary arterial hypertension and CFTR: the paradox of going forward by tacking sideways! Eur Respir J 2021;58:2101839. [PMID: 34824129 DOI: 10.1183/13993003.01839-2021] [Reference Citation Analysis]
12 Amaral MB, Rego S. [Rare diseases on the agenda for innovation in health: progress and challenges with cystic fibrosis]. Cad Saude Publica 2020;36:e00115720. [PMID: 33331552 DOI: 10.1590/0102-311X00115720] [Reference Citation Analysis]
13 Abreu SC, Lopes-Pacheco M, Weiss DJ, Rocco PRM. Mesenchymal Stromal Cell-Derived Extracellular Vesicles in Lung Diseases: Current Status and Perspectives. Front Cell Dev Biol 2021;9:600711. [PMID: 33659247 DOI: 10.3389/fcell.2021.600711] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
14 Mercier J, Ruffin M, Corvol H, Guillot L. Gene Therapy: A Possible Alternative to CFTR Modulators? Front Pharmacol 2021;12:648203. [PMID: 33967785 DOI: 10.3389/fphar.2021.648203] [Reference Citation Analysis]
15 Maisonneuve P, Lowenfels AB. Cancer in Cystic Fibrosis: A Narrative Review of Prevalence, Risk Factors, Screening, and Treatment Challenges. Chest 2021:S0012-3692(21)03858-7. [PMID: 34536383 DOI: 10.1016/j.chest.2021.09.003] [Reference Citation Analysis]
16 Hou C, Hu Y, Jiang H, Xu Z, Sha W, Liu J, Ren J, Yao M. Establishment of a 3D hyperuricemia model based on cultured human liver organoids. Free Radic Biol Med 2022;178:7-17. [PMID: 34823017 DOI: 10.1016/j.freeradbiomed.2021.11.023] [Reference Citation Analysis]
17 Akkerman-Nijland AM, Akkerman OW, Grasmeijer F, Hagedoorn P, Frijlink HW, Rottier BL, Koppelman GH, Touw DJ. The pharmacokinetics of antibiotics in cystic fibrosis. Expert Opin Drug Metab Toxicol 2021;17:53-68. [PMID: 33213220 DOI: 10.1080/17425255.2021.1836157] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
18 Wendekier C, Wendekier-Raybuck K. Cystic fibrosis: A changing landscape. Nursing 2021;51:32-8. [PMID: 34014874 DOI: 10.1097/01.NURSE.0000751344.57701.75] [Reference Citation Analysis]
19 Benninger LA, Trillo C, Lascano J. CFTR modulator use in post lung transplant recipients. J Heart Lung Transplant 2021;40:1498-501. [PMID: 34538541 DOI: 10.1016/j.healun.2021.08.009] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Gróf I, Bocsik A, Harazin A, Santa-Maria AR, Vizsnyiczai G, Barna L, Kiss L, Fűr G, Rakonczay Z Jr, Ambrus R, Szabó-Révész P, Gosselet F, Jaikumpun P, Szabó H, Zsembery Á, Deli MA. The Effect of Sodium Bicarbonate, a Beneficial Adjuvant Molecule in Cystic Fibrosis, on Bronchial Epithelial Cells Expressing a Wild-Type or Mutant CFTR Channel. Int J Mol Sci 2020;21:E4024. [PMID: 32512832 DOI: 10.3390/ijms21114024] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
21 Havermans T, Duff AJA. Changing landscape: psychological care in the era of cystic fibrosis transmembrane conductance regulator modulators. Curr Opin Pulm Med 2020;26:696-701. [PMID: 32941351 DOI: 10.1097/MCP.0000000000000727] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Lopes-pacheco M, Silva IA, Turner MJ, Carlile GW, Sondo E, Thomas DY, Pedemonte N, Hanrahan JW, Amaral MD. Characterization of the mechanism of action of RDR01752, a novel corrector of F508del-CFTR. Biochemical Pharmacology 2020;180:114133. [DOI: 10.1016/j.bcp.2020.114133] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
23 Blaho VA. Druggable Sphingolipid Pathways: Experimental Models and Clinical Opportunities. Adv Exp Med Biol 2020;1274:101-35. [PMID: 32894509 DOI: 10.1007/978-3-030-50621-6_6] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Shaw N, Collins S, Smith T, McCulloch A, Ketchell I, Edwards V, Blaikie L, Daniels T. Optimising the care and quality of life of people with cystic fibrosis: the influence of cystic fibrosis transmembrane conductance regulator modulators. Br J Hosp Med (Lond) 2021;82:1-6. [PMID: 34817261 DOI: 10.12968/hmed.2021.0530] [Reference Citation Analysis]
25 Gramegna A, Contarini M, Bindo F, Aliberti S, Blasi F. Elexacaftor-tezacaftor-ivacaftor: The new paradigm to treat people with cystic fibrosis with at least one p.Phe508del mutation. Curr Opin Pharmacol 2021;57:81-8. [PMID: 33582393 DOI: 10.1016/j.coph.2021.01.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
26 Jackson L, Waters V. Factors influencing the acquisition and eradication of early Pseudomonas aeruginosa infection in cystic fibrosis. J Cyst Fibros 2021;20:8-16. [PMID: 33172756 DOI: 10.1016/j.jcf.2020.10.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
27 Silva IAL, Railean V, Duarte A, Amaral MD. Personalized Medicine Based on Nasal Epithelial Cells: Comparative Studies with Rectal Biopsies and Intestinal Organoids. J Pers Med 2021;11:421. [PMID: 34065744 DOI: 10.3390/jpm11050421] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Clarke LA, Luz VCC, Targowski S, Ramalho SS, Farinha CM, Amaral MD. Integrity and Stability of PTC Bearing CFTR mRNA and Relevance to Future Modulator Therapies in Cystic Fibrosis. Genes (Basel) 2021;12:1810. [PMID: 34828417 DOI: 10.3390/genes12111810] [Reference Citation Analysis]
29 Valamparampil JJ, Gupte GL. Cystic fibrosis associated liver disease in children. World J Hepatol 2021; 13(11): 1727-1742 [PMID: 34904041 DOI: 10.4254/wjh.v13.i11.1727] [Reference Citation Analysis]
30 Wendekier C, Wendekier-Raybuck K. Cystic fibrosis: A changing landscape. Nurse Pract 2021;46:48-55. [PMID: 34424887 DOI: 10.1097/01.NPR.0000769756.82495.f3] [Reference Citation Analysis]
31 Dvorak V, Wiedmer T, Ingles-Prieto A, Altermatt P, Batoulis H, Bärenz F, Bender E, Digles D, Dürrenberger F, Heitman LH, IJzerman AP, Kell DB, Kickinger S, Körzö D, Leippe P, Licher T, Manolova V, Rizzetto R, Sassone F, Scarabottolo L, Schlessinger A, Schneider V, Sijben HJ, Steck AL, Sundström H, Tremolada S, Wilhelm M, Wright Muelas M, Zindel D, Steppan CM, Superti-Furga G. An Overview of Cell-Based Assay Platforms for the Solute Carrier Family of Transporters. Front Pharmacol 2021;12:722889. [PMID: 34447313 DOI: 10.3389/fphar.2021.722889] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
32 Al-Selwi Y, Shaw JA, Kattner N. Understanding the Pancreatic Islet Microenvironment in Cystic Fibrosis and the Extrinsic Pathways Leading to Cystic Fibrosis Related Diabetes. Clin Med Insights Endocrinol Diabetes 2021;14:11795514211048813. [PMID: 34675737 DOI: 10.1177/11795514211048813] [Reference Citation Analysis]
33 Lee JA, Cho A, Huang EN, Xu Y, Quach H, Hu J, Wong AP. Gene therapy for cystic fibrosis: new tools for precision medicine. J Transl Med 2021;19:452. [PMID: 34717671 DOI: 10.1186/s12967-021-03099-4] [Reference Citation Analysis]
34 Guerra L, Favia M, Di Gioia S, Laselva O, Bisogno A, Casavola V, Colombo C, Conese M. The preclinical discovery and development of the combination of ivacaftor + tezacaftor used to treat cystic fibrosis. Expert Opin Drug Discov 2020;15:873-91. [PMID: 32290721 DOI: 10.1080/17460441.2020.1750592] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
35 Vendrusculo FM, Donadio MVF, Pinto LA. Cystic fibrosis in Brazil: achievements in survival. J Bras Pneumol 2021;47:e20210140. [PMID: 33950101 DOI: 10.36416/1806-3756/e20210140] [Reference Citation Analysis]
36 Benden C, Schwarz C. CFTR Modulator Therapy and Its Impact on Lung Transplantation in Cystic Fibrosis. Pulm Ther 2021;7:377-93. [PMID: 34406641 DOI: 10.1007/s41030-021-00170-9] [Reference Citation Analysis]
37 Vogeser M. From therapeutic drug monitoring to total drug monitoring and drug-omics. Clinical Chemistry and Laboratory Medicine (CCLM) 2021;59:287-90. [DOI: 10.1515/cclm-2020-0339] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
38 Silva IAL, Duarte A, Marson FAL, Centeio R, Doušová T, Kunzelmann K, Amaral MD. Assessment of Distinct Electrophysiological Parameters in Rectal Biopsies for the Choice of the Best Diagnosis/Prognosis Biomarkers for Cystic Fibrosis. Front Physiol 2020;11:604580. [PMID: 33424627 DOI: 10.3389/fphys.2020.604580] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
39 Qiu F, Habgood M, Schneider-Futschik EK. The Balance between the Safety of Mother, Fetus, and Newborn Undergoing Cystic Fibrosis Transmembrane Conductance Regulator Treatments during Pregnancy. ACS Pharmacol Transl Sci 2020;3:835-43. [PMID: 33073185 DOI: 10.1021/acsptsci.0c00098] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
40 Poore TS, Hong G, Zemanick ET. Fungal Infection and Inflammation in Cystic Fibrosis. Pathogens 2021;10:618. [PMID: 34069863 DOI: 10.3390/pathogens10050618] [Reference Citation Analysis]
41 Mitri C, Xu Z, Bardin P, Corvol H, Touqui L, Tabary O. Novel Anti-Inflammatory Approaches for Cystic Fibrosis Lung Disease: Identification of Molecular Targets and Design of Innovative Therapies. Front Pharmacol 2020;11:1096. [PMID: 32848733 DOI: 10.3389/fphar.2020.01096] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
42 Wong XK, Yeong KY. A Patent Review on the Current Developments of Benzoxazoles in Drug Discovery. ChemMedChem 2021. [PMID: 34289258 DOI: 10.1002/cmdc.202100370] [Reference Citation Analysis]
43 Chart NA, Kisor DF, Farrell CL. Defining the role of pharmacists in medication-related genetic counseling. Per Med 2021;18:509-22. [PMID: 34402307 DOI: 10.2217/pme-2021-0005] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
44 Santuzzi CH, Liberato FMG, Morau SAC, de Oliveira NFF, Nascimento LR. Adherence and barriers to general and respiratory exercises in cystic fibrosis. Pediatr Pulmonol 2020;55:2646-52. [PMID: 32558990 DOI: 10.1002/ppul.24912] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
45 Mehta Z, Kamal KM, Miller R, Covvey JR, Giannetti V. Adherence to cystic fibrosis transmembrane conductance regulator (CFTR) modulators: analysis of a national specialty pharmacy database. J Drug Assess 2021;10:62-7. [PMID: 33968464 DOI: 10.1080/21556660.2021.1912352] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Ray TR, Ivanovic M, Curtis PM, Franklin D, Guventurk K, Jeang WJ, Chafetz J, Gaertner H, Young G, Rebollo S, Model JB, Lee SP, Ciraldo J, Reeder JT, Hourlier-Fargette A, Bandodkar AJ, Choi J, Aranyosi AJ, Ghaffari R, McColley SA, Haymond S, Rogers JA. Soft, skin-interfaced sweat stickers for cystic fibrosis diagnosis and management. Sci Transl Med 2021;13:eabd8109. [PMID: 33790027 DOI: 10.1126/scitranslmed.abd8109] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
47 Veit G, Roldan A, Hancock MA, Da Fonte DF, Xu H, Hussein M, Frenkiel S, Matouk E, Velkov T, Lukacs GL. Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination. JCI Insight 2020;5:139983. [PMID: 32853178 DOI: 10.1172/jci.insight.139983] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 14.5] [Reference Citation Analysis]
48 Shemie G, Nguyen MT, Wallenburg J, Ratjen F, Knoppers BM. The Equitable Implementation of Cystic Fibrosis Personalized Medicines in Canada. J Pers Med 2021;11:382. [PMID: 34067090 DOI: 10.3390/jpm11050382] [Reference Citation Analysis]
49 Pinto MC, Silva IAL, Figueira MF, Amaral MD, Lopes-Pacheco M. Pharmacological Modulation of Ion Channels for the Treatment of Cystic Fibrosis. J Exp Pharmacol 2021;13:693-723. [PMID: 34326672 DOI: 10.2147/JEP.S255377] [Reference Citation Analysis]
50 Laselva O, Guerra L, Castellani S, Favia M, Di Gioia S, Conese M. Small-molecule drugs for cystic fibrosis: Where are we now? Pulm Pharmacol Ther 2021;:102098. [PMID: 34793977 DOI: 10.1016/j.pupt.2021.102098] [Reference Citation Analysis]
51 Lopes-Pacheco M, Pedemonte N, Veit G. Discovery of CFTR modulators for the treatment of cystic fibrosis. Expert Opin Drug Discov 2021;16:897-913. [PMID: 33823716 DOI: 10.1080/17460441.2021.1912732] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
52 Fawcett LK, Wakefield CE, Sivam S, Middleton PG, Wark P, Widger J, Jaffe A, Waters SA. Avatar acceptability: views from the Australian Cystic Fibrosis community on the use of personalised organoid technology to guide treatment decisions. ERJ Open Res 2021;7:00448-2020. [PMID: 33532470 DOI: 10.1183/23120541.00448-2020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
53 Malagutti N, Fancello V, Cariani A, Battistini F, Fabbri C, Di Laora A, Valpiani G, Morotti C, Iannini V, Borin M, Ravani A, Bianchini C, Ciorba A, Stomeo F, Pelucchi S. Ion concentrations in nasal airway surface liquid: a prediction model for the identification of cystic fibrosis carriers. Rhinology 2021. [PMID: 34398939 DOI: 10.4193/Rhin21.064] [Reference Citation Analysis]
54 Jaques R, Shakeel A, Hoyle C. Novel therapeutic approaches for the management of cystic fibrosis. Multidiscip Respir Med 2020;15:690. [PMID: 33282281 DOI: 10.4081/mrm.2020.690] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
55 Pecoraro M, Franceschelli S, Pascale M. Lumacaftor and Matrine: Possible Therapeutic Combination to Counteract the Inflammatory Process in Cystic Fibrosis. Biomolecules 2021;11:422. [PMID: 33805605 DOI: 10.3390/biom11030422] [Reference Citation Analysis]
56 Kopel JJ, Bhutia YD, Sivaprakasam S, Ganapathy V. Consequences of NaCT/SLC13A5/mINDY deficiency: good versus evil, separated only by the blood-brain barrier. Biochem J 2021;478:463-86. [PMID: 33544126 DOI: 10.1042/BCJ20200877] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
57 Scotet V, L'Hostis C, Férec C. The Changing Epidemiology of Cystic Fibrosis: Incidence, Survival and Impact of the CFTR Gene Discovery. Genes (Basel) 2020;11:E589. [PMID: 32466381 DOI: 10.3390/genes11060589] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
58 Veit G, Velkov T, Xu H, Vadeboncoeur N, Bilodeau L, Matouk E, Lukacs GL. A Precision Medicine Approach to Optimize Modulator Therapy for Rare CFTR Folding Mutants. J Pers Med 2021;11:643. [PMID: 34357110 DOI: 10.3390/jpm11070643] [Reference Citation Analysis]
59 Santos L, Mention K, Cavusoglu-Doran K, Sanz DJ, Bacalhau M, Lopes-Pacheco M, Harrison PT, Farinha CM. Comparison of Cas9 and Cas12a CRISPR editing methods to correct the W1282X-CFTR mutation. J Cyst Fibros 2021:S1569-1993(21)00167-3. [PMID: 34103250 DOI: 10.1016/j.jcf.2021.05.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Ghigo A, Prono G, Riccardi E, De Rose V. Dysfunctional Inflammation in Cystic Fibrosis Airways: From Mechanisms to Novel Therapeutic Approaches. Int J Mol Sci 2021;22:1952. [PMID: 33669352 DOI: 10.3390/ijms22041952] [Reference Citation Analysis]
61 Girón Moreno RM, García-Clemente M, Diab-Cáceres L, Martínez-Vergara A, Martínez-García MÁ, Gómez-Punter RM. Treatment of Pulmonary Disease of Cystic Fibrosis: A Comprehensive Review. Antibiotics (Basel) 2021;10:486. [PMID: 33922413 DOI: 10.3390/antibiotics10050486] [Reference Citation Analysis]
62 Gnecco JS, Brown AT, Kan EL, Baugh L, Ives C, Loring M, Griffith LG. Physiomimetic Models of Adenomyosis. Semin Reprod Med 2020;38:179-96. [PMID: 33176387 DOI: 10.1055/s-0040-1719084] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
63 Zemanick ET, Taylor-Cousar JL, Davies J, Gibson RL, Mall MA, McKone EF, McNally P, Ramsey BW, Rayment JH, Rowe SM, Tullis E, Ahluwalia N, Chu C, Ho T, Moskowitz SM, Noel S, Tian S, Waltz D, Weinstock TG, Xuan F, Wainwright CE, McColley SA. A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele. Am J Respir Crit Care Med 2021;203:1522-32. [PMID: 33734030 DOI: 10.1164/rccm.202102-0509OC] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 9.0] [Reference Citation Analysis]
64 Mitri C, Sharma H, Corvol H, Tabary O. TMEM16A/ANO1: Current Strategies and Novel Drug Approaches for Cystic Fibrosis. Cells 2021;10:2867. [PMID: 34831090 DOI: 10.3390/cells10112867] [Reference Citation Analysis]
65 van der Meer R, Wilms EB, Heijerman HGM. CFTR Modulators: Does One Dose Fit All? J Pers Med 2021;11:458. [PMID: 34073663 DOI: 10.3390/jpm11060458] [Reference Citation Analysis]
66 Habler K, Kalla AS, Rychlik M, Bruegel M, Teupser D, Nährig S, Vogeser M, Paal M. Isotope dilution LC-MS/MS quantification of the cystic fibrosis transmembrane conductance regulator (CFTR) modulators ivacaftor, lumacaftor, tezacaftor, elexacaftor, and their major metabolites in human serum. Clin Chem Lab Med 2022;60:82-91. [PMID: 34668357 DOI: 10.1515/cclm-2021-0724] [Reference Citation Analysis]
67 Checa J, Aran JM. Airway Redox Homeostasis and Inflammation Gone Awry: From Molecular Pathogenesis to Emerging Therapeutics in Respiratory Pathology. Int J Mol Sci 2020;21:E9317. [PMID: 33297418 DOI: 10.3390/ijms21239317] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
68 Park JK, Shrivastava A, Zhang C, Pollok BA, Finkbeiner WE, Gibb ER, Ly NP, Illek B. Functional Profiling of CFTR-Directed Therapeutics Using Pediatric Patient-Derived Nasal Epithelial Cell Models. Front Pediatr 2020;8:536. [PMID: 33014932 DOI: 10.3389/fped.2020.00536] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
69 De Palma FDE, Raia V, Kroemer G, Maiuri MC. The Multifaceted Roles of MicroRNAs in Cystic Fibrosis. Diagnostics (Basel) 2020;10:E1102. [PMID: 33348555 DOI: 10.3390/diagnostics10121102] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
70 Völkner C, Pantoom S, Liedtke M, Lukas J, Hermann A, Frech MJ. Assessment of FDA-Approved Drugs as a Therapeutic Approach for Niemann-Pick Disease Type C1 Using Patient-Specific iPSC-Based Model Systems. Cells 2022;11:319. [DOI: 10.3390/cells11030319] [Reference Citation Analysis]
71 Garcia-Blanco MA. To Splice or Not to Splice, That Is the Treatment. Cell Chem Biol 2020;27:1453-5. [PMID: 33338466 DOI: 10.1016/j.chembiol.2020.12.002] [Reference Citation Analysis]
72 Vu A, McCray PB , Jr. New Directions in Pulmonary Gene Therapy. Hum Gene Ther 2020;31:921-39. [PMID: 32814451 DOI: 10.1089/hum.2020.166] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
73 Venturini A, Borrelli A, Musante I, Scudieri P, Capurro V, Renda M, Pedemonte N, Galietta LJV. Comprehensive Analysis of Combinatorial Pharmacological Treatments to Correct Nonsense Mutations in the CFTR Gene. Int J Mol Sci 2021;22:11972. [PMID: 34769402 DOI: 10.3390/ijms222111972] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
74 Harwood KH, McQuade RM, Jarnicki A, Schneider-Futschik EK. Anti-Inflammatory Influences of Cystic Fibrosis Transmembrane Conductance Regulator Drugs on Lung Inflammation in Cystic Fibrosis. Int J Mol Sci 2021;22:7606. [PMID: 34299226 DOI: 10.3390/ijms22147606] [Reference Citation Analysis]
75 Berg P, Jeppesen M, Leipziger J. Cystic fibrosis in the kidney: new lessons from impaired renal HCO3- excretion. Curr Opin Nephrol Hypertens 2021;30:437-43. [PMID: 34027905 DOI: 10.1097/MNH.0000000000000725] [Reference Citation Analysis]
76 Lopes-Pacheco M, Silva PL, Cruz FF, Battaglini D, Robba C, Pelosi P, Morales MM, Caruso Neves C, Rocco PRM. Pathogenesis of Multiple Organ Injury in COVID-19 and Potential Therapeutic Strategies. Front Physiol 2021;12:593223. [PMID: 33584343 DOI: 10.3389/fphys.2021.593223] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 12.0] [Reference Citation Analysis]
77 Zhang X, Hothi JS, Zhang YH, Ren A, Rock MJ, Srinivasan S, Stokes DC, Naren AP, Zhang W. F1099L-CFTR (c.3297C>G) has Impaired Channel Function and Associates with Mild Disease Phenotypes in Two Pediatric Patients. Life (Basel) 2021;11:131. [PMID: 33567498 DOI: 10.3390/life11020131] [Reference Citation Analysis]